ENTA
Enanta Pharmaceuticals Inc
11.90$
-1.0%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +84.0% | -0.4% | -23.1% | +48.9% | +237.0% | -45.1% | +16.5% | +101.0% | -0.7% | -40.3% | -20.7% | -11.2% | -8.1% | -14.6% | -3.4% | |
| – | – | +25.9% | +12.6% | +26.1% | +25.5% | +54.5% | +36.4% | +52.2% | – | – | – | – | -20.2% | – | – | |
| – | +84.0% | -0.4% | -23.1% | +48.9% | +237.0% | -45.1% | +16.5% | +101.0% | -0.7% | -40.3% | -20.7% | -11.2% | -8.1% | -14.6% | -10.2% | |
| – | +18.8% | +30.9% | +11.4% | +11.3% | +23.7% | +74.5% | +42.0% | +65.1% | +49.9% | -3.8% | +27.3% | -5.5% | -0.6% | -19.6% | -18.8% | |
| – | – | – | +16.6% | +62.0% | +35.2% | +25.3% | +22.3% | +13.0% | +12.0% | +4.2% | +18.9% | +39.8% | +16.3% | +9.4% | -24.1% | |
| – | +4.8% | +23.1% | +12.8% | +24.9% | +27.7% | +56.3% | +36.2% | +51.3% | +42.4% | -2.6% | +25.9% | +1.6% | +3.1% | -12.5% | -22.8% | |
| – | +264.4% | -15.9% | -57.6% | +110.3% | +553.9% | -75.2% | -20.2% | +258.9% | -58.4% | -213.3% | – | – | – | – | – | |
| – | – | -100.0% | – | -41.9% | -55.6% | +462.5% | -11.1% | +12,030.0% | +81.8% | +16.4% | -48.1% | -70.5% | +227.3% | +112.5% | -29.8% | |
| – | +200.9% | -8.2% | -55.0% | +100.1% | +551.1% | -74.0% | -17.2% | +245.6% | -51.1% | -176.9% | – | – | – | – | – | |
| – | – | – | – | – | – | -76.6% | -15.2% | +129.1% | -103.9% | – | -2,587.6% | – | – | -161.8% | – | |
| – | +194.9% | -8.2% | -55.0% | +257.7% | +129.4% | -72.6% | -18.3% | +306.3% | -35.5% | -178.0% | – | – | – | – | – | |
| – | +224.9% | -20.0% | -57.1% | +109.0% | +545.3% | -74.0% | -17.7% | +239.6% | -56.0% | -195.0% | – | – | – | – | – |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.